Table 1

Baseline characteristics

Pooled placebo0.5 mg
LAQ
1.0 mg
LAQ
1.5 mg
LAQ
2.0 mg
LAQ (n=29)
N6329302929
Age, years mean (SD)35.1 (10.9)39.6 (14.8)38.2 (11.3)40.9 (14.5)37.4 (9.9)
Female %*42.955.256.772.458.6
Predominately inflammatory disease %†54.075.966.741.441.4
CDAI score mean (SD)311.2 (74.5)288.3 (56.0)291.9 (57.5)297.8 (59.1)313.2 (58.9)
CRP concentration (mg/L)21.3 (27.8)17.1 (18.3)6.7 (12)15.1 (22.3)6.5 (17.1)
Median (IQR)
Min–max
1.8–85.72.2–127.51.0–153.61.0–79.81.0–153.2
CRP ≥5 mg/L at baseline %8186576645
Faecal calprotectin concentration (µg/g) median (IQR)475 (802)468 (1434)543 (813)318 (500)270 (422)
Min–max19.0–655915.0–655115.0–556318.0–800015.0–3994
Faecal calprotectin concentrations ≥250 µg/g at baseline %69.862.16051.737.9
Previous CD operations %33.317.240.044.844.8
Current treatment with either azathioprine, 6-mercaptopurine or methotrexate %31.727.636.737.924.1
Current treatment with 5-aminosalicylates %36.527.643.334.541.4
Current treatment with antibiotics %4.86.93.303.4
Current treatment with steroids %2734.5403117.2
Previous use of anti-TNF in past year %42.927.616.741.441.4
  • *% indicates per cent of patients.

  • †Montreal definition.

  • CD, Crohn's disease; CDAI, CD Activity Index; TNF, tumour necrosis factor.